You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
開拓藥業-B(9939.HK)高開近8% 普克魯胺治療住院新冠患者III期臨牀試驗獲巴西ANVISA批准
格隆匯 09-27 09:24
格隆匯9月27日丨上週五跳水一度暴跌近40%,最終收跌逾25%的開拓藥業-B(9939.HK)今早高開7.84%報55港元,市值213億港元。公司26日宣佈,普克魯胺治療住院新冠患者的III期全球多中心臨牀試驗已於當地時間9月22日獲巴西藥監部門ANVISA正式批准開展。這也是巴西ANVISA批准的第三項由開拓藥業主導開展的普克魯胺治療新冠的III期臨牀試驗。該項研究(NCT05009732)是一項隨機、雙盲、安慰劑對照、全球多中心的III期註冊性臨牀試驗,計劃招募1030名患者,旨在探索普克魯胺治療住院新冠患者的有效性和安全性。臨牀試驗的主要終點為30天內患者康復所需要的時間,次要終點為30天死亡率。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account